Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BR102375 is a non-TZD PPAR γ full agonist (EC50: 0.28 μM) for the treatment of type 2 diabetes.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | BR102375 is a non-TZD PPAR γ full agonist (EC50: 0.28 μM) for the treatment of type 2 diabetes. |
In vitro | BR102375 (Compound 18) (10 μM) increases gene expression levels relevant to PPARγ activation and enhances glucose uptake under insulin stimulation. BR102375 (10 nM, 100 nM, 1 μM; 6 days, 14 days) shows a concentration-dependent, insulin-sensitive effects on adipogenesis [1]. |
In vivo | BR102375 demonstrates efficacy in a mouse diabetes model, significantly suppressing the rise in random blood glucose levels (75 mpk, p.o., bid) and showing a decent effect on insulin resistance during the Oral Glucose Tolerance Test (OGTT). Additionally, it exhibits results on body weight gain that are nearly identical to those of Pioglitazone [1]. |
Molecular Weight | 554.64 |
Formula | C31H34N6O4 |
CAS No. | 2366255-59-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BR102375 2366255-59-4 Others BR 102375 BR-102375 inhibitor inhibit